Pieter H Reitsma
Overview
Explore the profile of Pieter H Reitsma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
122
Citations
2557
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schreuder M, Jourdi G, Veizaj D, Poole 3rd D, Cheung K, Poenou G, et al.
J Thromb Haemost
. 2024 May;
22(8):2211-2226.
PMID: 38729577
Background: Direct oral factor (F)Xa inhibitors are widely used as alternatives to conventional vitamin K antagonists in managing venous thromboembolism and nonvalvular atrial fibrillation. Unfortunately, bleeding-related adverse events remain a...
2.
Camilleri E, Ghobreyal M, Bos M, Reitsma P, van der Meer F, Swen J, et al.
Pharmacotherapy
. 2024 Apr;
44(6):416-424.
PMID: 38686648
Background: Major bleeding occurs annually in 1%-3% of patients on vitamin K antagonists (VKAs), despite close monitoring. Genetic variants in proteins involved in VKA response may affect this risk. Aim:...
3.
van Heteren D, Lijfering W, van der Meer F, Reitsma P, Swen J, Bos M, et al.
J Intern Med
. 2022 Sep;
293(1):124-127.
PMID: 36125842
No abstract available.
4.
Schreuder M, Liu X, Cheung K, Reitsma P, Nicolaes G, Bos M
Arterioscler Thromb Vasc Biol
. 2021 Jun;
41(8):2263-2276.
PMID: 34162230
OBJECTIVE: The Australian snake venom ptFV (Pseudonaja textilis venom-derived factor V) variant retains cofactor function
despite APC (activated protein C)-dependent proteolysis. Here, we aimed to unravel the mechanistic principles by...
5.
Verhoef D, Tjalma A, Cheung K, Reitsma P, Bos M
Thromb Res
. 2020 Dec;
198:154-162.
PMID: 33348189
A wide variety of animal models on thrombosis and hemostasis are used in thrombosis and hemostasis research for the preclinical assessment of hemostatic agents. While the vertebrate coagulome is highly...
6.
Toorop M, van Rein N, Cannegieter S, van der Meer F, Reitsma P, Lijfering W, et al.
Thromb Haemost
. 2020 Aug;
121(1):70-75.
PMID: 32854121
Background: Major bleeding occurs in 1 to 3% of patients treated with oral anticoagulants per year. Biomarkers may help to identify high-risk patients. A proposed marker for major bleeding while...
7.
Schreuder M, Poenou G, Strijbis V, Cheung K, Reitsma P, Bos M
Thromb Haemost
. 2020 Aug;
120(11):1512-1523.
PMID: 32820486
The venom of the Australian snake comprises powerful prothrombin activators consisting of factor X (v-ptFX)- and factor V-like proteins. While all vertebrate liver-expressed factor X (FX) homologs, including that of...
8.
Schreuder M, Reitsma P, Bos M
Semin Thromb Hemost
. 2020 Jul;
46(8):986-998.
PMID: 32688432
The direct oral anticoagulants targeting coagulation factor Xa or thrombin are widely used as alternatives to vitamin K antagonists in the management of venous thromboembolism and nonvalvular atrial fibrillation. In...
9.
Desch K, Ozel A, Halvorsen M, Jacobi P, Golden K, Underwood M, et al.
Blood
. 2020 May;
136(5):533-541.
PMID: 32457982
Deep vein thrombosis and pulmonary embolism, collectively defined as venous thromboembolism (VTE), are the third leading cause of cardiovascular death in the United States. Common genetic variants conferring increased varying...
10.
DAlessandro E, Becker C, Bergmeier W, Bode C, Bourne J, Brown H, et al.
Thromb Haemost
. 2020 Apr;
120(4):538-564.
PMID: 32289858
Thrombo-inflammation describes the complex interplay between blood coagulation and inflammation that plays a critical role in cardiovascular diseases. The third Maastricht Consensus Conference on Thrombosis assembled basic, translational, and clinical...